Table 3.
Cumulative productivity loss during phase II by treatment groups
| Variable | Mean (SD) or N (%) |
p Value* |
||||
|---|---|---|---|---|---|---|
| ETN25+MTX (n=39) | MTX (n=48) | PBO (n=32) | ETN+MTX−PBO | MTX−PBO | ETN+MTX−MTX | |
| Paid work productivity loss | ||||||
| Any paid work productivity loss, N (%) | 16 (41.0) | 21 (43.8) | 19 (59.4) | 0.274 | 0.423 | 0.959 |
| Paid work productivity loss, hours (SD) | 62.91 (144.28) | 82.84 (174.71) | 160.54 (312.50) | 0.243 | 0.431 | 0.846 |
| Percentage of paid work time loss (SD) | 0.07 (0.20) | 0.06 (0.11) | 0.11 (0.20) | 0.779 | 0.444 | 0.912 |
| Costs of lost paid work productivity loss, € (SD) | 963.54 (1980.41) | 1397.51 (2919.37) | 2518.61 (4322.05) | 0.159 | 0.430 | 0.717 |
| Unpaid work productivity loss | ||||||
| Any unpaid work productivity loss, N (%) | 5 (12.8) | 12 (24.5) | 14 (43.8) | 0.012 | 0.167 | 0.315 |
| Unpaid work productivity loss, hours (SD) | 49.67 (163.68) | 71.63 (227.78) | 172.25 (353.75) | 0.175 | 0.346 | 0.869 |
| Costs of lost unpaid work productivity loss, € (SD) | 368.89 (1215.68) | 532.04 (1691.8) | 1279.36 (2627.39) | 0.172 | 0.356 | 0.874 |
| Total costs of lost productivity | ||||||
| Any costs of lost productivity, N (%) | 18 (46.2) | 24 (50.0) | 21 (65.6) | 0.255 | 0.415 | 0.960 |
| Total costs, € (SD) | 1332.43 (2457.24) | 1940.63 (3595.19) | 3797.97 (6317.85) | 0.101 | 0.307 | 0.640 |
ETN25+MTX, etanercept 25 mg plus methotrexate; PBO, placebo.
*Bootstrapping method was used for multiple tests.